Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder

Published on February 7, 2022

The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.

Continue reading on website
Other news

The Assault on Productivity, Neglect of Your Calendar

February 7, 2022
Almost all of us want to be able to improve our productivity. But how exactly can we do this? There’s certainly no shortage of tried and true techniques. Examples would...

Top Research Reports for Bank of America, Coca-Cola & salesforce

February 7, 2022
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), The Coca-Cola Company (KO), and salesforce.com, inc. (CRM).